Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2- Advanced or Metastatic Breast Cancer”

120 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 120 results

Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Early research (Phase 1)Ended earlyNCT02964507
What this trial is testing

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Who this might be right for
Neoplasms
GlaxoSmithKline 124
Testing effectiveness (Phase 2)UnknownNCT05075512
What this trial is testing

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Breast Neoplasm Female
Zhejiang Cancer Hospital 40
Testing effectiveness (Phase 2)UnknownNCT02983071
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast CancerBreast Neoplasm
G1 Therapeutics, Inc. 102
Large-scale testing (Phase 3)Not Yet RecruitingNCT07340658
What this trial is testing

Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced, Metastatic Breast Cancer
Rovi Pharmaceuticals Laboratories 300
Large-scale testing (Phase 3)Active Not RecruitingNCT06764186
What this trial is testing

A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
AstraZeneca 101
Large-scale testing (Phase 3)UnknownNCT02404051
What this trial is testing

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CancerHormone Receptor Positive Tumor+2 more
Consorzio Oncotech 745
Not applicableLooking for participantsNCT07476170
What this trial is testing

Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China

Who this might be right for
HR+/HER2- Advanced or Metastatic Breast Cancer
Novartis Pharmaceuticals 14,000
Large-scale testing (Phase 3)Study completedNCT05054751
What this trial is testing

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Genor Biopharma Co., Ltd. 275
Early research (Phase 1)Active Not RecruitingNCT05266105
What this trial is testing

Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

Who this might be right for
Breast Cancer
Olema Pharmaceuticals, Inc. 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT06105632
What this trial is testing

Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Who this might be right for
Advanced or Metastatic Breast Cancer
Pfizer 333
Testing effectiveness (Phase 2)Study completedNCT05520723
What this trial is testing

Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED

Who this might be right for
Triple Negative Breast CancerBreast CancerAdvanced HR+/HER2- Breast Cancer
MedSIR 50
Testing effectiveness (Phase 2)Study completedNCT03839823
What this trial is testing

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 222
Testing effectiveness (Phase 2)UnknownNCT05044988
What this trial is testing

HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

Who this might be right for
HR+/HER2- Advanced and/or Metastatic Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Testing effectiveness (Phase 2)Looking for participantsNCT06201234
What this trial is testing

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast CancerAdvanced or Metastatic Breast CancerBRCA1 Mutation+1 more
GBG Forschungs GmbH 176
Early research (Phase 1)Looking for participantsNCT06515470
What this trial is testing

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Biotheryx, Inc. 82
Large-scale testing (Phase 3)Looking for participantsNCT06757634
What this trial is testing

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Who this might be right for
Breast Cancer
Celcuity Inc 1,180
Not applicableEnded earlyNCT04967248
What this trial is testing

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Who this might be right for
Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
Novartis Pharmaceuticals 4
Large-scale testing (Phase 3)Looking for participantsNCT07071337
What this trial is testing

SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Who this might be right for
Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 430
Early research (Phase 1)Active Not RecruitingNCT06299124
What this trial is testing

A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors

Who this might be right for
Breast CancerAdvanced Solid Tumor
Regor Pharmaceuticals Inc. 40
Next Page